65,437 trials
Colorectal Cancer (CRC)
Primary: Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater — 18 participants
Breast Neoplasms
Primary: Progression-Free Survival (PFS) — 8.6; 8.3; 8.2; 6.9 months — p=0.2651
Vaccines, Pneumococcal
Primary: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter…
Epilepsy
Primary: Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 4 Days) — 12 Subjects
Infections, Rotavirus
Primary: Number of Subjects Reporting Solicited General Symptoms — 204; 50; 405; 259 Participants
Macular Edema · Retinal Vein Occlusion
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months — 49.2; 47.4; 48.1; 0.8 Units on a scale — p=<0.0001
Myopia
Primary: Comfort Upon Insertion — 8.7; 9.2 Units on a Scale
Acute HIT II (Heparin-induced Thrombocytopenia Type II)
Primary: Number of Participants Diagnosed With Thrombosis and/or Pulmonary Embolism After the Occurrence of HIT II — 31; 4; 45; 78 participants
Attention Deficit Hyperactivity Disorder (ADHD) · Substance Use Disorder (SUD)
Primary: Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) Score — 19.4 Units on a scale
Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 4.4; 5.5 Months — p=0.0097
Chronic Myeloid Leukemia · Minimal Residual Disease
Primary: Response: One Log Decrease in BCR-ABL — 3; 7 Participants
Epilepsy
Primary: Number of Subjects Reporting at Least 1 Treatment-Emergent Adverse Event (TEAE) During the Treatment Period (up to 4 Days) — 21 Subjects
Attention-Deficit Hyperactivity Disorder
Primary: Power of Attention Score — 1260.7; 1324.1; 1272.8; 1244.6 milliseconds
Macular Edema · Retinal Vein Occlusion
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months — 54.7; 56.0; 53.0; 7.3 Units on a scale — p=<0.0001
Gout
Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001